Progress in Medicinal Chemistry
- 1st Edition, Volume 58 - March 14, 2019
- Latest edition
- Editors: David R. Witty, Brian Cox
- Language: English
Progress in Medicinal Chemistry, Volume 58, provides a review of eclectic developments in medicinal chemistry, with each chapter written by an international board of authors.… Read more
Data Mining & ML
Unlock the cutting edge
Up to 20% on trusted resources. Build expertise with data mining, ML methods.
Description
Description
Progress in Medicinal Chemistry, Volume 58, provides a review of eclectic developments in medicinal chemistry, with each chapter written by an international board of authors. Topics covered in this new release include Amyotrophic lateral sclerosis (ALS), Covalent-binding Drugs, Natural Product Drug Delivery – A Special Challenge?, and SMN2 gene splicing modifier, and more.
Key features
Key features
- Provides extended, timely reviews of topics in medicinal chemistry
- Contains targets and technologies relevant to the discovery of tomorrow’s drugs
- Presents analyses of successful drug discovery programs
Readership
Readership
Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes
Table of contents
Table of contents
1. Covalent binders in drug discovery
Maria A. Argiriadi, Aleksandra Baranczak, Michael M. Friedman, Julia Gavrilyuk, Adrian D. Hobson, Jonathan J. Hulce, Sami Osman, Noel S. Wilson and Anil Vasudevan
2. Amyotrophic lateral sclerosis
Klara Valko and Lukasz Ciesla
3. Rewriting the (tran)script: Application to spinal muscular atrophy
Hasane Ratni, Lutz Mueller and Martin Ebeling
4. Natural product drug delivery: A special challenge?
Neil J. Press, Emilie Joly and Peter Ertl
Product details
Product details
- Edition: 1
- Latest edition
- Volume: 58
- Published: March 14, 2019
- Language: English
About the editors
About the editors
DW
David R. Witty
In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.
David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.
Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.
BC